TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03952884

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise
Description: Prior to protein consumption participants will perform an acute bout of resistance exercise. They will warm up with two sets of 10 repetitions at 35-75% working load respectively, then perform four working sets of 10-12 repetitions at 65-70% of 1-RM. 1 min, 30 sec rest periods will be implemented between each set.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Prior to protein consumption participants will perform an acute bout of resistance exercise. They will warm up with two sets of 10 repetitions at 35-75% working load respectively, then perform four working sets of 10-12 repetitions at 65-70% of 1-RM. 1 min, 30 sec rest periods will be implemented between each set.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No Resistance Exercise
Description: Participants allocated to this group will not perform exercise prior to the administration of the nutritional intervention. Participants will remain at rest throughout the trial.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Resistance Exercise
Description: Participants allocated to this group will not perform exercise prior to the administration of the nutritional intervention. Participants will remain at rest throughout the trial.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Leucine
Description: Participants will be given 2g of leucine dissolved in 250mL of water. Drink will be consumed immediately after exercise or equivalent time point for non-exercise group.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dileucine
Description: Participants will be given 2g of dileucine dissolved in 250mL of water. Drink will be consumed immediately after exercise or equivalent time point for non-exercise group.
Study: NCT03775005

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: 3000 cGy in 10 daily fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: short course treatment
Description: 1800 cGy in 4 fractions administered twice a day
Study: NCT03955484

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary Glycosaminoglycan
Description: Urine will be collected from patients before and after one month of medical treatment (alpha-blocker). After being centrifuged at 5000 g for 10 minutes, urine will be stored at -80 ° C. At the end of the study, urinary glycosaminoglycan levels will be studied by spectrophotometric method.
Study: NCT02972697

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 11C-acetate ligand

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FDG ligand
Study: NCT02966080

Intervention type: DRUG
Group type: OTHER
Intervention: HEP-IV
Study: NCT03237481

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: Bupivacaine HCl without epinephrine, 75 mg by injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: Saline placebo by instillation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luer-lock applicator
Description: Applicator for instillation
Study: NCT02262429

Intervention type: OTHER
Intervention: ONS QIP
Description: Rapid comprehensive ONS, dietary consult, follow up phone calls

Intervention type: OTHER
Intervention: ONS Standard Feeding
Description: Standard of care
Study: NCT05658926

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Patients will learn how to use diaphragmatic breathing with mindfulness

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Education
Description: Patients will be provided with education regarding the Gate Control Theory of Pain.
Study: NCT00506935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVG
Description: 5 grams GVG

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT00636454

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping skills training (CST) for chronic pain
Description: Participants will attend 10 sessions lasting between 45 and 60 minutes each. Topics will include relaxation training, managing activity cycles, and changing thought patterns to reduce the negative effects of pain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will receive the care usually given to patients with knee or hip OA.
Study: NCT04279925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ORIF (Open reduction internal fixation): locally-made miniplate and screw
Description: Fracture lines in this group underwent open reduction internal fixation (ORIF) procedure which consists of realignment of the bone achieved from surgical mean and stabilization of the bone fragments by using locally-made miniplate and screw produced by the Faculty of Engineering Universitas Indonesia. The plate used in the study is a straight plate with 4 and 5 holes with the dimension of 17mm long, 4 mm wide and 0.56 mm thick.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ORIF: Imported miniplate and screw
Description: Fracture lines in this group underwent open reduction internal fixation (ORIF) procedure which consists of realignment of the bone achieved from surgical mean and stabilization of the bone fragments by using Biomet® miniplate 1.5 produced by Biomet, included in the Lorenz® Plating System Midface. The particular plate used in the study is a straight plate with 4 holes, 17mm length and 0.6mm thick, coded 01-7047 in the catalog. Biomet® screw 1.5 utilized in this study is also produced by Biomet, included in the Lorenz® Plating System Midface. The dimension of the screw is 4mm length, 1.5 mm diameter, and coded 91-6104 1.5 mm X-Drive Self drilling screws.
Study: NCT03109834

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Meal replacement (MR)
Description: MR-WL group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1200 kcal/d and was advised to replace two meals, i.e. breakfast and dinner, every day with two MR shakes, soups or bars and to prepare their own lunch during 3-month weight loss phase (phase 1).~During 3-month weight stabilization phase (phase 2) MR-S group (MR group during weight stabilization phase) were encouraged to consume a self-directed well-balanced variety of nutrient-dense foods without meal intervention. MR counted to food choice option. The MR-S group was instructed to continue the implemented nutrition advice of weight loss phase.~Duration: 6 months (phase 1 and phase 2: baseline I - 6.month)

Intervention type: OTHER
Group type: OTHER
Intervention: Control (C)
Description: During 3-month weight loss phase (phase 1) C-WL group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1200 kcal/d without MR for weight control.~During 3-month weight stabilization (phase 2) phase C-S group (C group during weight stabilization phase) were encouraged to consume a self-directed well-balanced variety of nutrient-dense foods without meal intervention. MR counted to food choice option. The C-S group was instructed to continue the implemented nutrition advice of weight loss phase.~Duration: 6 months (phase 1 and phase 2: baseline I - 6.month)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Verum
Description: Verum: Specific micronutrient composition with omega-3 fatty acids (capsules)~Verum group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1500 kcal/d and was advised to consume 3 verum-capsules twice a day (with breakfast and dinner) with 200 ml water during 6-month weight loss maintenance phase (phase 3).~Duration: 6 months (6.month / baseline II - 12.month)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1500 kcal/d and was advised to consume 3 placebo-capsules twice a day (with breakfast and dinner) with 200 ml water during 6-month weight loss maintenance phase.~Placebo contains no micronutrients and omega-3 fatty acids.~Duration: 6 months (6.month / baseline II - 12.month)
Study: NCT02815111

Intervention type: DRUG
Intervention: Ketamine
Description: Receive an analgesic regimen that involves Ketamine infusions

Intervention type: DRUG
Intervention: Lidocaine
Description: Receive an analgesic regimen that involves Lidocaine infusions

Intervention type: DRUG
Intervention: Acetaminophen
Description: May be administered Acetaminophen rectally, by mouth, or intravenously in patients not suitable for either of the other methods of administration

Intervention type: DRUG
Intervention: Neurontin
Description: May be given Neurontin by mouth as an approved medication for pain control
Study: NCT03267238

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbial Transplantation
Description: Fecal Microbial Transplantation via will be offered to eligible Crohn's patient
Study: NCT05289102

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Two postpartum visits.
Description: Group 1 serves as an intervention group (experimental). All enrolled women in the intervention group were in connection with the inclusion given two pre-booked postpartum care visits. One early at 3 weeks and one later at 7 weeks postpartum.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One postpartum visit.
Description: Group 2 serves as a control group (active comparator). All enrolled women in the control group were in connection with the inclusion given one pre-booked postpartum care visit at 7 weeks postpartum according to the traditional postpartum care.
Study: NCT01709058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intramuscular/paravertebral injections of Oxygen-Ozone
Description: Medical Oxygen will be used as a part of the injected mixture (100% oxygen, 200 bar compressed gas in steel cylinder with valve 14 with an integrated reductive). For the generation of the Oxygen-Ozone mixture a certified equipment OZONOSAN alpha plus will be used according to the D.L. 46/97, EEC Directive 93/42, class 2A with a photometer. The mixture of O2-O3 is produced through a method called silent discharge. Intramuscular/paravertebral injections to 3 cm from the spinal medial line will be performed introducing 5-20 mL of oxygen-ozone to each point, at a concentration of 10-20 micrograms/mL, for a total volume of 40 mL

Intervention type: OTHER
Group type: OTHER
Intervention: Simulated intramuscular/paravertebral injections
Description: The simulated treatment administration will mimic the treatment in the area to be treated by pricking the skin with the needle without drilling. A light massage will be practice by hand and the application area will be covered with a bandage adhesive leaving the patient in the prone position for 10-15 minutes.
Study: NCT04273958

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality helmet
Description: During a painful procedure, the patient will watch a virtual world in a virtual reality helmet, while wearing a noise-canceling headset with soothing music.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Computer screen
Description: During a painful procedure, the patient will watch the same virtual world, while wearing a noise-canceling headset with the same soothing music.
Study: NCT02723617

Intervention type: OTHER
Group type: OTHER
Intervention: MED 0.5
Description: Participants will be fed a Mediterranean diet providing 0.5 oz. per day of lean beef.

Intervention type: OTHER
Group type: OTHER
Intervention: MED 2.5
Description: Participants will be fed a Mediterranean diet providing 2.5 oz. per day of lean beef.

Intervention type: OTHER
Group type: OTHER
Intervention: MED 5.5
Description: Participants will be fed a Mediterranean diet providing 5.5 oz. per day of lean beef.

Intervention type: OTHER
Group type: OTHER
Intervention: AAD 2.5
Description: Participants will be fed an average American diet providing 2.5 oz. per day of lean beef.
Study: NCT01911364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDP/FF/GB
Description: Superiority over Tiotropium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Superiority of CHF5993 over Tiotropium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BDP/FF + Tiotropium
Description: non inferiority vs CHF5993
Study: NCT02251535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ATTUNE® Knee System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ATTUNE® Knee System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFC® SIGMA® Knee System
Study: NCT03237481

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Luer-lock applicator
Description: Applicator for instillation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vial access device
Description: Device for withdrawal of drug product
Study: NCT04390100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyaluronic acid (Gengiegel 0.2% oral gel )
Description: coverage of the free gingival graft area in the palate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich fibrin
Description: coverage of the free gingival graft area in the palate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gel foam
Description: coverage of the free gingival graft area in the palate
Study: NCT03025165

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Adherence Clubs
Description: Provision of ART care in the community to a club of 20-25 HIV+ patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-Based ART Delivery
Description: Provision of ART care to an individual at their home

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Delivery of ART adherence support, symptom screening and dispensation of medications at the local clinic according to local guidelines.
Study: NCT00889421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: oral dose of 30 mg BID for 6 months
Study: NCT03136601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PTNS maintenance
Description: The intervention is the timing of PTNS for maintenance (monthly treatment versus as patient needs)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PTNS maintenance
Description: The intervention is the timing of PTNS for maintenance (monthly treatment versus as patient needs)
Study: NCT03314987

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-carnosine
Description: a naturally occurring di-peptide

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: an identically appearing supplement
Study: NCT01721200

Intervention type: OTHER
Group type: OTHER
Intervention: Decision Support Tool
Description: Educational decision support tool for patients with rheumatoid arthritis
Study: NCT01958918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0.5 mg intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: 2 mg intravitreal injection
Study: NCT01319006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863A
Description: 100mg (x90=13um), oral tablet, single-dose with 7 day wash-out
Study: NCT01721200

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Subjects randomized to the Usual Care Group will receive their biologic drug teaching from the rheumatologist as part of their routine care.
Study: NCT01319006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863A
Description: 100mg (x90=13um), oral tablet, single-dose with 7 day wash-out

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863A
Description: 100mg (x90=13um), oral tablet, single-dose with 7 day wash-out

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863A
Description: 100mg (x90=29um), oral tablet, single-dose with 7 day wash-out

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863A
Description: 100mg (x90=29um), oral tablet, single-dose with 7 day wash-out

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863A
Description: 100mg (x90=29um), oral tablet, single-dose with 7 day wash-out

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863A
Description: 100mg (x90=41um), oral tablet, single-dose with 7 day wash-out

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863A
Description: 100mg (x90=41um), oral tablet, single-dose with 7 day wash-out

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863A
Description: 100mg (x90=41um), oral tablet, single-dose with 7 day wash-out
Study: NCT04191759

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Test-Retest reproducibility
Description: Protocol is the same for extended or flexed knee. The testing apparatus was set up as described in the constructor owner's manual and subjects were positioned in the supine lying position. The After a 5 min rest period, the participant's ankle is passively stretched through slow loading cycles from 15° of ankle flexion to 35° of ankle extension. Oral instruction is given to the participants to stay relaxed and avoid any muscle contraction and movement of the leg throughout the passive stretching. To familiarize, participant have 3 repetitions of passive ankle flexion-extension at 5°.s-1, and after 2min rest, data are collected from one repetitions at 5°.s-1 in passive mode. The measurements are also performed at an angular rate of 90°.s-1, according to the same protocol. Data for maximal voluntary isokinetic contraction are collected from 3 maximal repetitions at 60°.s-1 in concentric mode and participant are encouraged by constant verbal stimulation.
Study: NCT01278446

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed, whey protein infant formula
Description: New hydrolyzed formula
Study: NCT04425226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection [Keytruda]
Description: Pembrolizumab (Keytruda, MSD China) is a recombinant anti-human PD-1 monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Oral Product
Description: Lenvatinib (Lenvima, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT
Study: NCT03736525

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Design For Wellness (DWELL)
Description: Design for wellness is an online Facebook intervention. During 3 months intervention period, participants in the intervention group will be exposed to contents on their newsfeed (posts on Facebook wall), and also be expected and encouraged to create new content themselves. The contents will be interactive and involve different modes of delivery, as audio and video, to reinforce active learning. Participants will be part of DWELL Facebook group community and will be empowered to read and control cues in the environment, by developing skills to enhance their self-efficacy.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait list control group
Description: Wait list control group will get no intervention during the study period. Participants will answer questionnaires pre, mid and post intervention. A delayed form of the intervention will be available to them after the close of the study.
Study: NCT04090736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Pevonedistat 20 mg/m2 intravenous on days 1, 3, and 5 (28-day cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine 75 mg/m2 subcutaneous on a 5-on/2-off \[weekend\]/2-on schedule (28-day cycle). Intravenous for patients who have non-tolerated local reactions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Azacitidine 75 mg/m2 subcutaneous on a 5-on/2-off \[weekend\]/2-on schedule (28-day cycle). Intravenous for patients who have non-tolerated local reactions
Study: NCT02753751

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AKI Alert
Description: Provider's will receive a pop-up alert in the electronic health record until AKI is documented in the problem list or AKI resolves.
Study: NCT02265705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT02703844

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Caloric Vestibular Stimulation
Description: Stimulation of the vestibular nerves

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Caloric Vestibular Stimulation
Description: Sham stimulation of the vestibular nerves
Study: NCT01047683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMR101 (ethyl icosapentate) - 4 g/day
Description: AMR101 (ethyl icosapentate) 4 capsules/day for 12 weeks (Weeks 1-12)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMR101 (ethyl icosapentate) - 2 g/day
Description: AMR101 (ethyl icosapentate) 2 capsules/day with placebo 2 capsules/day for 12 weeks (Weeks 1-12)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 4 capsules/day for 12 weeks (Weeks 1-12)
Study: NCT03701477

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trans-diagnostic cognitive-behavioral therapy
Description: 10 therapeutic sessions hold in groups of 5-10 individuals. Details about each session: Session 1: Establishing rapport, psychoeducation; Session 2: Relaxation, hierarchy development; Session 3: Identifying automatic negative thoughts, guided imaginary; Session 4: Cognitive restructuring; Session 5: Problem solving skills training, distraction; Session 6: Exposure-based procedures, cognitive restructuring; Session 7-9: Advanced cognitive restructuring, stress management, assertiveness skills training, preparation for termination phase; Session 10: Relapse prevention, termination

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: General relaxation/stress management therapeutic session
Description: Patients will attend a 3-hour meeting in which basic techniques of relaxation and stress management will be discussed.
Study: NCT00614939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: 2.5 mg once daily oral dose

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Placebo
Description: Placebo
Study: NCT00824109

Intervention type: DEVICE
Group type: OTHER
Intervention: Second Generation Anti-Microbial bifurcated vascular graft (InterGard)
Description: treatment of patients with aorto-iliac occlusion,stenosis, or aneurysm
Study: NCT02379598

Intervention type: DIETARY_SUPPLEMENT
Intervention: Aminoacid based formula
Description: Formula based on aminoacid

Intervention type: DIETARY_SUPPLEMENT
Intervention: Hydrolyzed whey formula
Description: Formula based on hydrolyzed whey protein